Clinical Trial Update: A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 trial of BMS-986315 in combination with nivolumab and chemotherapy for first-line Stage IV or recurrent non-small cell lung cancer was terminated, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BMS-986315
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: NSCLC | Phase 2 | Status: TERMINATED | Results posted: 2025-04-16